Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers (Q43262208)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Andrew M Scott

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Rebecca A Herbertson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Niall C Tebbutt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Fook-Thean Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

David J MacFarlane

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Bridget Chappell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Noel Micallef

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Sze-Ting Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Timothy Saunder

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Wendie Hopkins

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Fiona E Smyth

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

John Bellen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Daryl S Sonnichsen

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Martin W Brechbiel

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Carmel Murone

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

13 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

6709-6715

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

9 February 2020

cites work

1 reference

12 December 2020

Fucosylated type-2 chain polylactosamine antigens in human lung cancer

1 reference

12 December 2020

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

1 reference

12 December 2020

Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens

1 reference

12 December 2020

Hepatic and extrahepatic scavenger receptors: function in relation to disease

1 reference

12 December 2020

Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma

1 reference

12 December 2020

Immunohistologic expression of blood-group antigens in normal human gastrointestinal tract and colonic carcinoma.

1 reference

12 December 2020

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake

1 reference

12 December 2020

Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver

1 reference

12 December 2020

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

12 December 2020

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer

1 reference

12 December 2020

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

12 December 2020

Activation-dependent expression of the blood group-related lewis Y antigen on peripheral blood granulocytes

1 reference

12 December 2020

A CT assisted method for absolute quantitation of internal radioactivity.

1 reference

12 December 2020

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

1 reference

12 December 2020

Glycolipids carrying Le(y) are preferentially expressed on small-cell lung cancer cells as detected by the monoclonal antibody MLuC1

1 reference

12 December 2020

Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors

1 reference

12 December 2020

Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants

1 reference

12 December 2020

A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.

1 reference

12 December 2020

Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters

1 reference

12 December 2020

Effect of size and charge on endocytosis of lysozyme derivatives by sinusoidal rat liver cells in vivo

1 reference

12 December 2020

Expression of Lewisa, Lewisb, X, and Y blood group antigens in human colonic tumors and normal tissue and in human tumor-derived cell lines

1 reference

12 December 2020

Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer

1 reference

12 December 2020

10.1158/1078-0432.CCR-09-0536

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19825951%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

19825951

1 reference